Does Cell Type Affect Mesothelioma Prognosis?
Yes, cell type is one of the most important factors affecting mesothelioma prognosis. Epithelioid mesothelioma has the best prognosis, sarcomatoid has the poorest, and biphasic falls between the two depending on the proportion of each cell type present.
The Three Mesothelioma Cell Types
Mesothelioma is classified into three histological subtypes based on the appearance and behavior of the cancer cells. These subtypes are determined through biopsy and pathological examination and have a direct impact on treatment options and expected outcomes.
The three cell types are epithelioid, sarcomatoid, and biphasic. Each behaves differently in terms of growth rate, spread pattern, and response to treatment. Accurate identification of cell type is essential for developing an effective treatment plan.
Epithelioid vs. Sarcomatoid Prognosis
Epithelioid mesothelioma cells tend to grow more slowly and are more responsive to chemotherapy and surgical intervention. Patients with purely epithelioid tumors typically have the longest median survival — often 12 to 24 months, and sometimes significantly longer with aggressive multimodal treatment.
Sarcomatoid mesothelioma cells are more aggressive, spread more rapidly, and are generally more resistant to standard treatments. Median survival for sarcomatoid patients is approximately 6 to 8 months. These tumors are less likely to respond to chemotherapy and are often not amenable to curative surgery.
Biphasic Mesothelioma and Treatment Implications
Biphasic mesothelioma contains both epithelioid and sarcomatoid cells. The prognosis for biphasic cases depends largely on the proportion of each cell type — tumors with a higher percentage of epithelioid cells tend to behave more favorably and respond better to treatment.
Regardless of cell type, patients should consult with experienced mesothelioma specialists who can recommend the most appropriate treatment approach. Pursuing compensation for asbestos exposure can help ensure access to specialized care and support for patients and their families.
- Epithelioid: Most common (50–70% of cases), best prognosis, median survival 12–24 months
- Sarcomatoid: Least common (10–20%), poorest prognosis, median survival 6–8 months
- Biphasic: Mixed cell type (20–30%), prognosis varies based on epithelioid-to-sarcomatoid ratio
- Treatment Response: Epithelioid cells respond most favorably to chemotherapy and surgery
Reviewed by: Paul Danziger, J.D. — Texas Bar — 30+ years mesothelioma litigation
Last updated: March 15, 2026
Sources: World Health Organization — Classification of Tumours: Thoracic Tumours, Journal of Thoracic Oncology — Histological Subtypes and Prognosis in Mesothelioma, Cancer — Impact of Histology on Survival in Malignant Pleural Mesothelioma
Our attorneys have handled mesothelioma cases for over 30 years. We can evaluate your situation, explain every option available to you, and answer your questions — all at no cost and with no obligation.
Request a Free Consultation
Your information is confidential and protected. We typically respond within 24 hours.
Call 1-800-400-1805 for immediate help.